{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:05:35Z","timestamp":1792800335034,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Roche Pharma AG","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"https:\/\/ror.org\/00sh68184","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Huntington\u2019s disease (HD) is a rare, genetic, neurodegenerative and ultimately fatal disease with no cure or progression-delaying treatment currently available. HD is characterized by a triad of cognitive, behavioural and motor symptoms. Evidence on epidemiology and management of HD is limited, especially for Germany. This study aims to estimate the incidence and prevalence of HD and analyze the current routine care based on German claims data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The source of data was a sample of the Institute for Applied Health Research Berlin (InGef) Research Database, comprising data of approximately four million insured persons from approximately 70 German statutory health insurances. The study was conducted in a retrospective cross-sectional design using 2015 and 2016 as a two-year observation period. At least two outpatient or inpatient ICD-10 codes for HD (ICD-10: G10) during the study period were required for case identification. Patients were considered incident if no HD diagnoses in the 4 years prior to the year of case identification were documented. Information on outpatient drug dispensations, medical aids and remedies were considered to describe the current treatment situation of HD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A 2-year incidence of 1.8 per 100,000 persons (95%-Confidence interval (CI): 1.4\u20132.4) and a 2-year period prevalence of 9.3 per 100,000 persons (95%-CI: 8.3\u201310.4) was observed. The prevalence of HD increased with advancing age, peaking at 60\u201369\u2009years (16.8 per 100,000 persons; 95%-CI: 13.4\u201321.0) and decreasing afterwards.<\/jats:p>\n                    <jats:p>The most frequently observed comorbidities and disease-associated symptoms in HD patients were depression (42.9%), dementia (37.7%), urinary incontinence (32.5%), extrapyramidal and movement disorders (30.5%), dysphagia (28.6%) and disorders of the lipoprotein metabolism (28.2%).<\/jats:p>\n                    <jats:p>The most common medications in HD patients were antipsychotics (66.9%), followed by antidepressants (45.1%). Anticonvulsants (16.6%), opioids (14.6%) and hypnotics (9.7%) were observed less frequently.<\/jats:p>\n                    <jats:p>Physical therapy was the most often used medical aid in HD patients (46.4%). Nursing services and speech therapy were used by 27.9 and 22.7% of HD patients, respectively, whereas use of psychotherapy was rare (3.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on a representative sample, this study provides new insights into the epidemiology and routine care of HD patients in Germany, and thus, may serve as a starting point for further research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-019-1556-3","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T10:04:49Z","timestamp":1575972289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Epidemiology and health care utilization of patients suffering from Huntington\u2019s disease in Germany: real world evidence based on German claims data"],"prefix":"10.1186","volume":"19","author":[{"given":"Christoph","family":"Ohlmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Uwe","family":"Saum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Galetzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Beier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Gothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"issue":"9557","key":"1556_CR1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO. Huntington\u2019s disease. Lancet. 2007;369(9557):218\u201328.","journal-title":"Lancet"},{"issue":"4","key":"1556_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204\u201316.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1556_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2017","unstructured":"McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol. 2017;25(1):24\u201334.","journal-title":"Eur J Neurol"},{"issue":"Supplement 2","key":"1556_CR4","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.3949\/ccjm.79.s2a.06","volume":"79","author":"C Singer","year":"2012","unstructured":"Singer C. Comprehensive treatment of Huntington disease and other choreic disorders. Cleve Clin J Med. 2012;79(Supplement 2):S30\u20134.","journal-title":"Cleve Clin J Med"},{"key":"1556_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"Roos RAC","year":"2010","unstructured":"Roos RAC. Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"1556_CR6","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012;27(9):1083\u201391.","journal-title":"Mov Disord"},{"issue":"2","key":"1556_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"MD Rawlins","year":"2016","unstructured":"Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJ, Smeeth L. The prevalence of Huntington's disease. Neuroepidemiology. 2016;46(2):144\u201353.","journal-title":"Neuroepidemiology"},{"key":"1556_CR8","volume-title":"Regulation (EC) No 141\/2000 of the European Parliament and of the council of 16 December 1999 on orphan medicinal products","author":"European Parliament","year":"2000","unstructured":"European Parliament. Regulation (EC) No 141\/2000 of the European Parliament and of the council of 16 December 1999 on orphan medicinal products. Brussels: European Parliament; 2000."},{"issue":"1","key":"1556_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/cge.12385","volume":"86","author":"C Kay","year":"2014","unstructured":"Kay C, Skotte NH, Southwell AL, Hayden MR. Personalized gene silencing therapeutics for Huntington disease. Clin Genet. 2014;86(1):29\u201336.","journal-title":"Clin Genet"},{"key":"1556_CR10","first-page":"424","volume":"58","author":"H Przuntek","year":"1987","unstructured":"Przuntek H, Steigerwald A. Epidemiologische Untersuchung zur Huntington\u2019schen Erkrankung im Einzugsgebiet der W\u00fcrzburger Neurologischen Universit\u00e4tsklinik unter besonderer Ber\u00fccksichtigung des unterfr\u00e4nkischen Raumes. Nervenarzt. 1987;58:424\u20137.","journal-title":"Nervenarzt"},{"key":"1556_CR11","first-page":"1","volume-title":"Humangenetic: Advances in Human Genetics","author":"GG Wendt","year":"1972","unstructured":"Wendt GG, Drohm D. Huntington\u2019s chorea. A population-genetic study. Die Huntingtonsche Chorea. In: Humangenetic: Advances in Human Genetics. Stuttgart: Thieme; 1972. p. 1\u2013121."},{"key":"1556_CR12","doi-asserted-by":"publisher","first-page":"RRN1206","DOI":"10.1371\/currents.RRN1206","volume":"3","author":"M Busse","year":"2011","unstructured":"Busse M, Al-Madfai DH, Kenkre J, Landwehrmeyer GB, Bentivoglio A, Rosser A. European Huntington\u2019s Disease N: utilisation of healthcare and associated Services in Huntington\u2019s disease: a data mining study. PLoS Curr. 2011;3:RRN1206.","journal-title":"PLoS Curr"},{"issue":"1","key":"1556_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn F, Walker J. Characteristics and external validity of the German health risk institute (HRI) database. Pharmacoepidemiol Drug Saf. 2016;25(1):106\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1556_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2217\/nmt-2016-0008","volume":"6","author":"SS Baig","year":"2016","unstructured":"Baig SS, Strong M, Quarrell OW. The global prevalence of Huntington's disease: a systematic review and discussion. Neurodegenerative Dis Manag. 2016;6(4):331\u201343.","journal-title":"Neurodegenerative Dis Manag"},{"issue":"10","key":"1556_CR15","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","volume":"84","author":"SJ Evans","year":"2013","unstructured":"Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry. 2013;84(10):1156\u201360.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1556_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000444230","volume":"46","author":"J Sipil\u00e4","year":"2016","unstructured":"Sipil\u00e4 J, P\u00e4iv\u00e4rinta M. Why we still need more research on the epidemiology of Huntington\u2019s disease. Neuroepidemiology. 2016;46:154\u20135.","journal-title":"Neuroepidemiology"},{"issue":"9751","key":"1556_CR17","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/S0140-6736(10)61988-5","volume":"376","author":"CT Loy","year":"2010","unstructured":"Loy CT, Lownie A, McCusker E. Huntington\u2019s disease. Lancet. 2010;376(9751):1463.","journal-title":"Lancet"},{"issue":"5","key":"1556_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ejhg.2010.229","volume":"19","author":"SC Warby","year":"2011","unstructured":"Warby SC, Visscher H, Collins JA, Doty CN, Carter C, Butland SL, Hayden AR, Kanazawa I, Ross CJ, Hayden MR. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur J Hum Genet. 2011;19(5):561\u20136.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"1556_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mds.25717","volume":"29","author":"ER Fisher","year":"2014","unstructured":"Fisher ER, Hayden MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord. 2014;29(1):105\u201314.","journal-title":"Mov Disord"},{"issue":"1","key":"1556_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.parkreldis.2014.10.025","volume":"21","author":"JO Sipil\u00e4","year":"2015","unstructured":"Sipil\u00e4 JO, Hietala M, Siitonen A, Paivarinta M, Majamaa K. Epidemiology of Huntington's disease in Finland. Parkinsonism Relat Disord. 2015;21(1):46\u20139.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1\u20132","key":"1556_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000479697","volume":"49","author":"E Carrassi","year":"2017","unstructured":"Carrassi E, Pugliatti M, Govoni V, Sensi M, Casetta I, Granieri E. Epidemiological study of Huntington's disease in the province of Ferrara, Italy. Neuroepidemiology. 2017;49(1\u20132):18\u201323.","journal-title":"Neuroepidemiology"},{"key":"1556_CR22","doi-asserted-by":"crossref","unstructured":"Wexler NS, Collett L, Wexler A, Rawlins MD, Tabrizi SJ, Douglas I, Smeeth L, Evans SJ. Incidence of adult Huntington\u2019s disease in the UK: a UK-based primary care study and a systematic review. BMJ Open. 2015; https:\/\/bmjopen.bmj.com\/content\/bmjopen\/6\/2\/e009070.full.pdf. Cited 2019 Mar 13.","DOI":"10.1136\/bmjopen-2015-009070"},{"issue":"4","key":"1556_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1176\/jnp.17.4.496","volume":"17","author":"JS Paulsen","year":"2005","unstructured":"Paulsen JS, Nehl C, Hoth KF, Kanz JE, Benjamin M, Conybeare R, McDowell B, Turner B. Depression and stages of Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci. 2005;17(4):496\u2013502.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"8","key":"1556_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3111\/13696998.2013.818545","volume":"16","author":"V Divino","year":"2013","unstructured":"Divino V, Dekoven M, Warner JH, Giuliano J, Anderson KE, Langbehn D, Lee WC. The direct medical costs of Huntington\u2019s disease by stage. A retrospective commercial and Medicaid claims data analysis. J Med Econ. 2013;16(8):1043\u201350.","journal-title":"J Med Econ"},{"issue":"1","key":"1556_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12955-016-0575-7","volume":"15","author":"MR van Walsem","year":"2017","unstructured":"van Walsem MR, Howe EI, Ruud GA, Frich JC, Andelic N. Health-related quality of life and unmet healthcare needs in Huntington\u2019s disease. Health Qual Life Outcomes. 2017;15(1):6.","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"1556_CR26","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1176\/ps.62.10.pss6210_1159","volume":"62","author":"K Noyes","year":"2011","unstructured":"Noyes K, Liu H, Lyness JM, Friedman B. Medicare beneficiaries with depression: comparing diagnoses in claims data with the results of screening. Psychiatr Serv. 2011;62(10):1159\u201366.","journal-title":"Psychiatr Serv"},{"issue":"9","key":"1556_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.healthpol.2016.07.008","volume":"120","author":"J Frank","year":"2016","unstructured":"Frank J. Comparing nationwide prevalences of hypertension and depression based on claims data and survey data: an example from Germany. Health policy. 2016;120(9):1061\u20139.","journal-title":"Health policy"},{"issue":"5\u20136","key":"1556_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00103-013-1688-3","volume":"56","author":"MA Busch","year":"2013","unstructured":"Busch MA, Maske UE, Ryl L, Schlack R, Hapke U. Prevalence of depressive symptoms and diagnosed depression among adults in Germany: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5\u20136):733\u20139.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"1","key":"1556_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1037\/a0020937","volume":"25","author":"JC Stout","year":"2011","unstructured":"Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn DR, et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology. 2011;25(1):1\u201314.","journal-title":"Neuropsychology"},{"issue":"8","key":"1556_CR30","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","volume":"79","author":"JS Paulsen","year":"2008","unstructured":"Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, et al. Detection of Huntington\u2019s disease decades before diagnosis: the predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874\u201380.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1556_CR31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.psychres.2010.04.030","volume":"178","author":"LJ Beglinger","year":"2010","unstructured":"Beglinger LJ, O'Rourke JJ, Wang C, Langbehn DR, Duff K, Paulsen JS. Huntington study group I: earliest functional declines in Huntington disease. Psychiatry Res. 2010;178(2):414\u20138.","journal-title":"Psychiatry Res"},{"issue":"9","key":"1556_CR32","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/mds.22953","volume":"25","author":"GM Peavy","year":"2010","unstructured":"Peavy GM, Jacobson MW, Goldstein JL, Hamilton JM, Kane A, Gamst AC, Lessig SL, Lee JC, Corey-Bloom J. Cognitive and functional decline in Huntington's disease: dementia criteria revisited. Mov Disord. 2010;25(9):1163\u20139.","journal-title":"Mov Disord"},{"issue":"5","key":"1556_CR33","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","volume":"11","author":"JS Paulsen","year":"2011","unstructured":"Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep. 2011;11(5):474\u201383.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"1556_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/JHD-140124","volume":"3","author":"KE Anderson","year":"2014","unstructured":"Anderson KE, Divino V, DeKoven M, Langbehn D, Warner JH, Giuliano J, Lee WC. Interventional differences among Huntington\u2019s disease patients by disease progression in commercial and medicaid populations. J Huntingtons Dis. 2014;3(4):355\u201363.","journal-title":"J Huntingtons Dis"},{"key":"1556_CR35","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3389\/fneur.2018.00930","volume":"9","author":"NP Rocha","year":"2018","unstructured":"Rocha NP, Mwangi B, Gutierrez Candano CA, Sampaio C, Furr Stimming E, Teixeira AL. The Clinical Picture of Psychosis in Manifest Huntington's Disease: A Comprehensive Analysis of the Enroll-HD Database. Front Neurol. 2018;9:930.","journal-title":"Front Neurol"},{"key":"1556_CR36","first-page":"RRN1184","volume":"2","author":"M Orth","year":"2010","unstructured":"Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB. Investigators of the European Huntington's Disease N: Observing Huntington\u2019s disease: the European Huntington\u2019s disease Network\u2019s REGISTRY. PLoS Curr. 2010;2:RRN1184.","journal-title":"PLoS Curr"},{"key":"1556_CR37","doi-asserted-by":"publisher","first-page":"RRN1260","DOI":"10.1371\/currents.RRN1260","volume":"3","author":"J Burgunder","year":"2011","unstructured":"Burgunder J, Guttman M, Perlman S, Goodman N, van Kammen D, Goodman L. An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease. PLoS Curr. 2011;3:RRN1260.","journal-title":"PLoS Curr"},{"issue":"1","key":"1556_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","volume":"77","author":"EM Coppen","year":"2017","unstructured":"Coppen EM, Roos RAC. Current pharmacological approaches to reduce chorea in Huntington\u2019s disease. Drugs. 2017;77(1):29\u201346.","journal-title":"Drugs"},{"issue":"1","key":"1556_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1517\/14656566.2016.1109630","volume":"17","author":"SL Mason","year":"2015","unstructured":"Mason SL, Barker RA. Advancing pharmacotherapy for treating Huntington\u2019s disease: a reviewof the existing literature. Expert Opin Pharmacother. 2015;17(1):41\u201352.","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"1556_CR40","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/ene.13107","volume":"23","author":"C Jones","year":"2016","unstructured":"Jones C, Busse M, Quinn L, Dawes H, Drew C, Kelson M, Hood K, Rosser A, Edwards RT. The societal cost of Huntington\u2019s disease: are we underestimating the burden? Eur J Neurol. 2016;23(10):1588\u201390.","journal-title":"Eur J Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1556-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T20:20:49Z","timestamp":1607458849000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1556-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1556-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"12 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patient-level data in the InGef research database are de-identified to comply with German data protection regulations. Use of the study database for health services research is therefore fully compliant with German federal law and, accordingly, institutional review board\/ethical approval and informed consent of the patient was not needed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was funded by Roche Pharma AG. The authors had complete autonomy for the process of establishing the protocol, carrying out the analyses and interpreting the results. This also includes the full right to publish the results without limitation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}